The mysterious coronavirus outbreak in the Chinese town Wuhan, now termed as COVID-19, and its fast spread to many other nations, endangers thousands of lives. The pandemic has catalyzed the development of novel coronavirus vaccines across the biotech sector, both by pharmaceutical companies and research organizations like the National Institutes of Health (NIH), US.
Inovio Pharmaceuticals intends to begin clinical trials on a coronavirus vaccine in April this year. Health officials from WHO have noticed that Gilead’s remdesivir has shown efficacy in treating the coronavirus disease.
Chloroquine approved by US FDA
The US Food and Drug Administration (FDA) approved limited emergency use for chloroquine and hydroxychloroquine for a remedy for COVID-19.
The President of the USA, Donald Trump, had announced on 19 March that chloroquine and hydroxychloroquine/Plaquenil, used to treat malaria and arthritis, were approved by the FDA to be tested as a treatment.
Chloroquine has been tested in various clinical trials conducted by government agencies and academic institutions. Other antivirals medications are also intended to be fast-tracked for testing for coronavirus.
Favilavir, the first approved coronavirus medication in China
The National Medical Products Administration of China has approved using Favilavir, an anti-viral drug, as a remedy for coronavirus. The medication has reportedly shown efficacy in treating the disease with minimal side effects in a clinical trial involving 70 patients. The clinical trial has been conducted in Shenzhen, Guangdong province.
Pharmaceutical companies involved in developing coronavirus drugs/vaccines
Here’s a list of the significant coronavirus drugs that pharmaceutical companies throughout the world are growing that have the potential to become major coronavirus vaccines or antivirals.
Novel coronavirus vaccines
Listed below are the coronavirus vaccines in various stages of development, around the globe.
Fusogenix DNA vaccine by Entos Pharmaceuticals
Entos Pharmaceuticals is developing Fusogenix DNA vaccine developed with the Fusogenix drug delivery platform to prevent COVID-19 infections. Fusogenix drug delivery system is a proteo-lipid automobile that introduces genetic payload directly into the cells.
Entos is working on creating an optimized payload comprising multiple protein epitopes derived from SARS-COV-2 proteins, which will provoke an immune reaction in the body to prevent COVID-19 disease.
ChAdOx1 nCoV-19 by University of Oxford
The university is testing the vaccine in a clinical trial intended to be run at the Thames Valley Region. Approximately 510 volunteers aged between 18 years and 55 years will be registered for the study.
Gimsilumab by Roivant Sciences
Roivant Sciences is progressing the development of Gimsilumab a clinical-stage, human monoclonal antibody. The medication targets granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a pro-inflammatory cytokine found in elevated levels in the serum of COVID-19 patients.
Targeting GM-CSF is predicted to reduce lung damage and reduce the mortality rate in COVID-19 patients.
AdCOVID by Altimmune
The business is currently carrying out immunogenicity studies after, which phase one clinical trial material will be developed. Altimmune and UAB will work with researchers to conduct preclinical animal studies and phase one clinical trial in the third quarter of 2020.
TJM2 by I-Mab Biopharma
I-Mab Biopharma is developed TJM2, a neutralizing antibody, as a remedy for cytokine storm in patients suffering from a serious case of coronavirus infection. The medication targets the human granulocyte-macrophage colony-stimulating variable (GM-CSF), which is responsible for acute and chronic inflammation.
The business will start development after receiving approval for the Investigational New Drug (IND) program from the U.S.
Coronavirus vaccine by Medicago
Medicago is growing drug candidates against COVID-19 after having generated Virus-Like Particles (VLP) of the coronavirus.
The provider’s research activities are being partially funded by the Canadian Institutes for Health Research (CIHR).
AT-100 by Airway Therapeutics
Airway Therapeutics is researching its own publication human recombinant protein called AT-100 (rhSP-D) as a remedy for coronavirus.